Sagimet Biosciences (STU:0O2) Debt-to-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Sagimet Biosciences Debt-to-Asset?

Sagimet Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.07 Mil. Sagimet Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.00 Mil. Sagimet Biosciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was €153.05 Mil. Sagimet Biosciences's debt to asset for the quarter that ended in Dec. 2024 was 0.00.

Sagimet Biosciences Debt-to-Asset Historical Data

The historical data trend for Sagimet Biosciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sagimet Biosciences Debt-to-Asset Chart

Sagimet Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.01

Sagimet Biosciences Quarterly Data
	Dec19	Mar20	Dec20	Mar21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Sagimet Biosciences's Debt-to-Asset

For the Biotechnology subindustry, Sagimet Biosciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sagimet Biosciences's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Sagimet Biosciences's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Sagimet Biosciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Sagimet Biosciences's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.074	+	0)	/	153.047
	=	0.00

Sagimet Biosciences's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.074	+	0)	/	153.047
	=	0.00

Sagimet Biosciences (STU:0O2) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Sagimet Biosciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Sagimet Biosciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sagimet Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sagimet Biosciences Inc (STU:0O2) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

SGMT:USA 0O2:Germany

Address

155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402

Website

https://www.sagimet.com

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Sagimet Biosciences Headlines

No Headlines